The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer
- PMID: 29143072
- DOI: 10.1007/s00280-017-3476-5
The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer
Abstract
Objectives: Chemotherapy-related acute exacerbation (AE) of interstitial lung disease (ILD) is observed in certain patients with non-small cell lung cancer (NSCLC) who have ILD. Although the prognosis of AE-ILD is extremely poor, there are no established risk factors for its occurrence. Therefore, we retrospectively investigated whether high-resolution computed tomography (HRCT) findings could identify risk factors for AE-ILD.
Materials and methods: Between January 2005 and December 2016, 35 patients with NSCLC who received chemotherapy at Hiroshima University Hospital and were diagnosed with ILD on HRCT were enrolled. The extent of ground-glass attenuation (GGA), reticulation, honeycomb appearance, and emphysema, as well as the presence of micronodules, traction bronchiectasis, and consolidation were evaluated in five levels of the lung bilaterally. The HRCT scores of GGA, reticulation, honeycomb appearance, and emphysema were determined by the following formula: 100 × sum of the extent of the HRCT findings/lung area.
Results: Thirty-five patients underwent various first- to fifth-line chemotherapy regimens. Nine patients (25.7%) developed AE-ILD. The median HRCT scores of GGA and reticulation were significantly higher in patients with AE-ILD than in those without. On univariate analysis, a GGA area score ≥ 24.8, reticulation area score ≥ 19.5, and KL-6 level ≥ 946 U/mL were significant risk factors. Multivariate logistic analysis revealed that only a GGA area score ≥ 24.8 was an independent risk factor of AE-ILD.
Conclusions: The GGA area on HRCT is a risk factor for chemotherapy-related AE-ILD. Therefore, this parameter can be used to predict the risk of AE-ILD before administering chemotherapy.
Keywords: Acute exacerbation; Chemotherapy; High-resolution computed tomography; Interstitial lung disease; Lung cancer.
Similar articles
-
The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.Int J Clin Oncol. 2020 Feb;25(2):282-291. doi: 10.1007/s10147-019-01576-x. Epub 2019 Nov 13. Int J Clin Oncol. 2020. PMID: 31720993
-
Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.Lung Cancer. 2016 Jun;96:63-7. doi: 10.1016/j.lungcan.2016.03.017. Epub 2016 Mar 30. Lung Cancer. 2016. PMID: 27133752
-
The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.Tumori. 2017 Jan 21;103(1):60-65. doi: 10.5301/tj.5000574. Epub 2016 Oct 22. Tumori. 2017. PMID: 27791236
-
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.Respir Investig. 2018 Jul;56(4):307-311. doi: 10.1016/j.resinv.2018.03.002. Epub 2018 Apr 13. Respir Investig. 2018. PMID: 29764748 Review.
-
Diagnosis and management of drug-associated interstitial lung disease.Br J Cancer. 2004 Aug;91 Suppl 2(Suppl 2):S24-30. doi: 10.1038/sj.bjc.6602064. Br J Cancer. 2004. PMID: 15340375 Free PMC article. Review.
Cited by
-
Mesenchymal-epithelial Transition Exon 14-skipping Mutation-positive Invasive Mucinous Adenocarcinoma of the Lung: First Case Treated with Mesenchymal-epithelial Transition-tyrosine Kinase Inhibitors.Intern Med. 2024 Jun 15;63(12):1789-1795. doi: 10.2169/internalmedicine.2540-23. Epub 2023 Nov 13. Intern Med. 2024. PMID: 37952955 Free PMC article.
-
The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.Int J Clin Oncol. 2020 Feb;25(2):282-291. doi: 10.1007/s10147-019-01576-x. Epub 2019 Nov 13. Int J Clin Oncol. 2020. PMID: 31720993
-
Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease.Intern Med. 2020 Aug 15;59(16):1939-1945. doi: 10.2169/internalmedicine.4552-20. Epub 2020 May 8. Intern Med. 2020. PMID: 32389949 Free PMC article.
-
A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities.Oncologist. 2020 Nov;25(11):e1589-e1592. doi: 10.1634/theoncologist.2020-0266. Epub 2020 Sep 14. Oncologist. 2020. PMID: 32701167 Free PMC article.
-
Diagnostic value of KL-6 in idiopathic interstitial pneumonia.J Thorac Dis. 2018 Aug;10(8):4724-4732. doi: 10.21037/jtd.2018.07.54. J Thorac Dis. 2018. PMID: 30233844 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials